CTA
PTCT icon

Carillon Tower Advisers’s PTC Therapeutics PTCT Stock Holding History

Carillon Tower Advisers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$18.1M Sell
296,107
-15,897
-5% -$937K 0.11% 262
2020
Q3 		$14.6M Buy
312,004
+15,897
+5% +$783K 0.19% 198
2020
Q2 		$15M Buy
+296,107
New +$14.5M 0.12% 245

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Carillon Tower Advisers's PTCT Position: Q4 2020 in Review

Carillon Tower Advisers reduced its PTC Therapeutics (PTCT) stake by 5.1% in Q4 2020, selling an estimated $937K and leaving 296,107 shares worth $18.1M. The position accounts for 0.11% of the portfolio, ranked #262.

Carillon Tower Advisers first reported a position in PTCT in Q2 2020 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold PTCT as of Q4 2020.

  • Carillon Tower Advisers held 296,107 shares of PTC Therapeutics worth $18.1M as of Q4 2020.
  • Carillon Tower Advisers sold 15,897 PTC Therapeutics shares in Q4 2020, an estimated $937K.
  • PTC Therapeutics made up 0.11% of Carillon Tower Advisers's portfolio in Q4 2020, its #262 holding.
  • Carillon Tower Advisers first reported a position in PTC Therapeutics in Q2 2020 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.